Home

Sutro Biopharma, Inc. - Common Stock (STRO)

1.0500
+0.1753 (20.04%)
NASDAQ · Last Trade: May 1st, 2:41 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise --
By Vaxcyte, Inc. · Via GlobeNewswire · November 27, 2023
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via MarketBeat · October 31, 2022